Pfizer CEO Albert Bourla says major acquisitions are done. With $6-7B left for bolt-on deals, Pfizer focuses on executing Seagen, Biohaven and Metsera assets.
If analysts and investors think that Pfizer has a trick up its sleeve to further acquire its way to growth, CEO Albert Bourla assured them …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Pfizer unveils additional $2.5B in planned cost savings through 2029
Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts
'Better every quarter': Bayer CEO stays course on turnaround plan as pharma sales underwhelm in Q2
Pfizer has pursued deals of all sizes to build new revenue streams, but the outlook underscores that those investments are still…
Pfizer is looking to newer products and acquisitions to offset a declining Covid business.
Pfizer will reduce its costs by $2.5 billion in another round of cutbacks which will kick in next year and run through 2029. |…
Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical…
Pfizer is spending more than $7 billion to buy biotech Metsera to try to catch cup in the obesity drug market.
Novartis, Vertex, Ipsen and United Therapeutics kick off second-half M&A activity with up to $12.6B in new deals, extending a…
